课题基金 / 基金详情

Defining Pathways in COPD Patient Oriented Research

Defining Pathways in COPD Patient Oriented Research
定义以 COPD 患者为导向的研究途径
批准号:
10674684
负责人:
MeiLan K Han
金额:
$12.28万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-07-01 至 2027-07-31

项目摘要

项目成果

MeiLan K Han的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 博士Han是一名医生科学家,专注于慢性阻塞性肺疾病(COPD)患者导向 研究(POR)。此更新应用程序将继续确保她有受保护的时间专注于指导 和职业发展。韩博士的职业目标是继续开发COPD POR项目, 了解这种疾病隐含的疾病异质性,以便最终可以 开发从这个奖项的保护时间将允许她采取额外的课程,以获得新的 分析和指导技能。她的指导目标在这个奖项将保留保护时间 继续培训居民,研究员,研究生和初级教师,特别是初级 研究者,特别是女性和少数民族,目前在COPD POR中代表性不足。韩博士 将继续为每个受训者量身定制辅导计划,包括一对一辅导课程, 与统计人员合作,提供分析方法方面的正规教育机会, 进行研究。密歇根大学(UM)提供的资源,包括UM肺 部门多学科培训补助金和密歇根临床与健康研究所/临床与 转化科学奖为POR培训提供了理想的基础设施。韩博士的科学目的是 拟议预算将利用几个新供资的项目,为初级调查员提供培训机会。 新出现的数据表明,COPD在生命中开始的时间比以前认识到的要早得多。CT分析 UM开发的技术(参数响应映射,PRM)可以识别小气道疾病, 被认为是肺气肿的先兆病变。Han博士是SPIROMICS队列扩展的共同主要研究者 (HL 144718)正在招募30-55岁的有COPD风险或轻度至 中度COPD。在目标1中,我们将使用这些数据在早期COPD,以确定是否PRM 可以在这样的个体中鉴定确定的小气道疾病以预测疾病进展。第二 本提案具体目的将使用R 01(HL 150023)生成的数据,Han博士联系PI。在Aim中 2.将在COPDGene队列中进行纵向PRM分析,以确定10年纵向PRM 吸烟者和既往吸烟者中小气道疾病和肺气肿的演变轨迹 年龄40-80岁,有或无COPD。这些分析共同提供了一种新的成像生物标志物的数据 在整个寿命和疾病严重程度谱,并提供了丰富的研究机会, investigators.韩博士正处于职业生涯的理想阶段,可以利用K24奖项。她深感 致力于COPD POR的调查事业该应用程序还符合两个NHLBI任务:(1) 促进肺部疾病预防和治疗的研究、培训和教育;以及(2) 增加我们国家肺病研究队伍的多样性。
英文摘要
ABSTRACT Dr. Han is a physician scientist with a focus in chronic obstructive pulmonary disease (COPD) patient-oriented research (POR). This renewal application will continue to secure her with protected time to focus on mentoring and career development. Dr. Han’s career goal is to continue developing a COPD POR program to better understand disease heterogeneity implicit to this disease so that ultimately disease modifying therapies can be developed. Protected time from this award would allow her to take additional coursework to acquire new analytic and mentoring skills. Her mentoring objectives under this award will be to retain protected time to continue to train residents, fellows, graduate students and junior faculty, focusing in particular on junior investigators, in particular women and minorities, who are currently underrepresented in COPD POR. Dr. Han will continue to tailor mentoring plans to each trainee, consisting of one-on-one mentoring sessions, collaboration with statisticians and formal educational opportunities in analytic methods and the responsible conduct of research. The resources available at the University of Michigan (UM) including the UM Pulmonary Division Multidisciplinary Training Grant and the Michigan Institute for Clinical & Health Research/Clinical & Translational Science Award provide an ideal infrastructure for POR training. Dr. Han’s scientific aims for this proposal will leverage several newly funded projects to provide training opportunities for junior investigators. Emerging data suggest that COPD begins much earlier in life than previously appreciated. CT analytic techniques (Parametric Response Mapping, PRM) developed at UM can identify small airway disease, believed to be the precursor lesion to emphysema. Dr. Han is Co-PI of an extension to the SPIROMICS cohort (HL144718) that is recruiting 30-55 year-old current and former smokers either at risk for COPD or with mild to moderate established COPD. In Aim 1, we will use these data in early COPD to determine whether PRM defined small airways disease can be identified in such individuals to predict disease progression. The second specific aim of this proposal will use data generated by R01 (HL150023) for which Dr. Han is contact PI. In Aim 2, longitudinal PRM analyses in the COPDGene cohort will be performed to determine 10-year longitudinal trajectories for evolution of small airways disease and emphysema among at risk current and former smokers aged 40-80, with and without COPD. Together these analyses provide data on a novel imaging biomarker across the lifespan and disease severity spectrum and provide a wealth of research opportunities for junior investigators. Dr. Han is at an ideal stage of her career to take advantage of a K24 award. She is deeply committed to her investigative career in COPD POR. This application also aligns with two NHLBI missions: (1) to promote research, training, and education for the prevention and treatment of lung disease; and (2) increasing the diversity of our national lung disease research workforce.
期刊论文(32)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1146/annurev-med-080919-112707
发表时间: 2021-01-27
期刊: Annual review of medicine
影响因子: 10.5
作者: [Ferrera MC, Labaki WW, Han MK]
通讯作者: Han MK
Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.
SPIROMICS COPD 队列中血液嗜酸性粒细胞绝对计数低的临床意义。
DOI: 10.1016/j.chest.2022.10.029
发表时间: 2023
期刊: Chest
影响因子: 9.6
作者: [LeMaster,WBlake, Quibrera,PMiguel, Couper,David, Tashkin,DonaldP, Bleecker,EugeneR, Doerschuk,ClaireM, Ortega,VictorE, Cooper,Christopher, Han,MeiLanK, Woodruff,PrescottG, O'Neal,WandaK, Anderson,WayneH, Alexis,NeilE, Bowler,Russe]
通讯作者: Bowler,Russe
DOI: 10.1016/j.ccm.2021.04.014
发表时间: 2021-09
期刊: Clinics in chest medicine
影响因子: 5.7
作者: [Criner RN, Al-Abcha A, Lambert AA, Han MK]
通讯作者: Han MK
COPD in Women: Future Challenges.
女性慢性阻塞性肺病:未来的挑战。
DOI: 10.1016/j.arbres.2022.06.008
发表时间: 2023
期刊: Archivos de bronconeumologia
影响因子: 8
作者: [Scicluna,Victoria, Han,MeiLan]
通讯作者: Han,MeiLan
共 15 条
    Defining Pathways in COPD Patient Oriented Research
    The CAPTURE Study: Validating a unique COPD screening tool in primary care
    The CAPTURE Study: Validating a unique COPD screening tool in primary care
    Defining Pathways in COPD Patient Oriented Research
    国内基金
    海外基金
    补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
    靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
    • 批准号:
      JCZRQN202500010
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位:
    对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
    • 批准号:
      2025JJ70209
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      雷芬芳
    • 依托单位:
    AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      万荣
    • 依托单位: